UCB shares dip, analysts flag prescription data slowdown for BimzelX

UCB SA

31/10/2025 13:03

** Shares in Belgian drugmaker UCB UCB.BR slide about 5% to their lowest price in a month

** Two analysts point to a slowdown in early prescription data for its flagship skin disease product, BimzelX

** One analyst, who preferred to be unnamed, notes that disruptions at prescription data gatherer IQVIA add to uncertainty, as UCB has said data for October will be restated but has not released when that would be

** The drop follows a downgrade from Jefferies earlier this week saying the "BimzelX bonanza" showed signs of steadying pace

** UCB could not be reached by phone and did not immediately respond to an emailed request for a comment

 (Reporting by Jakob Van Calster and Jerome Terroy)

 ((jakob.vancalster@thomsonreuters.com))